Summary

U.S. Large And Small-scale Bioprocessing Market Summary

The U.S. large and small-scale bioprocessing market size was estimated at USD 24.86 billion in 2024 and is projected to reach USD 67.34 billion by 2033, growing at a CAGR of 11.24% from 2025 to 2033. This growth is driven by the rising global demand for biologics, including monoclonal antibodies, vaccines, and cell and gene therapies.

Biopharmaceutical companies are increasingly investing in flexible manufacturing solutions, such as single-use technologies and modular bioprocessing systems, to accelerate development timelines and reduce costs.

Growing Adoption of Single-Use Technologies in U.S. Bioprocessing

The increasing implementation of single-use technology (SUT) is transforming the U.S. large- and small-scale bioprocessing market, enabling greater flexibility, operational efficiency, and cost-effectiveness in biologics manufacturing. Single-use systems, including bioreactors, bags, filters, connectors, and tubing, are increasingly favored over traditional stainless-steel setups, particularly for small-batch and multiproduct facilities. Their ability to reduce cleaning validation, lower the risk of cross-contamination, and minimize turnaround times makes them highly suitable for modern, fast-paced bioproduction environments. As the demand for personalized medicine and modular manufacturing grows, SUT adoption is accelerating across both clinical and commercial stages.

Biopharmaceutical companies and CDMOs are leveraging single-use technologies to streamline scale-up processes, shorten development timelines, and meet the increasing need for agile production. These systems are particularly valuable in early-stage manufacturing, where flexibility and speed are critical. The growth of cell and gene therapies, which often require small, high-value batches, is further driving the shift toward SUT-based infrastructure. Additionally, the rise of multiproduct facilities demands rapid changeovers, which are more efficiently supported by single-use components than traditional clean-in-place systems.

Manufacturers of bioprocessing equipment are continuously innovating within the SUT space to enhance performance, durability, and compatibility with complex biologics. Developments such as gamma-stable polymers, automation-integrated systems, and scalable single-use platforms are expanding the applicability of SUTs beyond early-stage production to include commercial-scale operations. Key industry players are also investing in hybrid bioprocessing models, combining single-use and stainless-steel systems, to balance cost, scale, and compliance. This trend reflects the evolving needs of manufacturers to customize production environments based on batch size, product type, and regulatory requirements.

Looking ahead, the growth trajectory of SUT in the U.S. bioprocessing market is supported by strong regulatory acceptance, increasing investment in flexible manufacturing facilities, and the expanding pipeline of biologics and advanced therapies. The technology’s ability to reduce capital expenditure, operational risk, and production downtime positions it as a core enabler of next-generation biomanufacturing. As the industry continues to prioritize speed, safety, and scalability, single-use systems are expected to play an even more central role in shaping the future of bioprocessing in the U.S.

U.S. Large And Small-Scale Bioprocessing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. large and small-scale bioprocessing market based on scale, workflow, product, application, use-type, and mode:

• Scale Outlook (Revenue, USD Million, 2021 - 2033)
• Industrial Scale (Over 50,000 Liter)
• Small Scale (Less Than 50,000 Liter)
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Downstream Processing
• Fermentation
• Upstream Processing
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Bioreactors/Fermenters
• Cell Culture Products
• Filtration Assemblies
• Bioreactors Accessories
• Bags & Containers
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceuticals
• Speciality Industrial Chemicals
• Environmental Aids
• Use-Type Outlook (Revenue, USD Million, 2021 - 2033)
• Multi-Use
• Single-Use
• Mode Outlook (Revenue, USD Million, 2021 - 2033)
• In-House
• Outsourced

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Scale Segment
1.2.2. Workflow Segment
1.2.3. Product Segment
1.2.4. Application Segment
1.2.5. Use-type Segment
1.2.6. Mode Segment
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. U.S. Large and Small-scale Bioprocessing Market Variables & Trends
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing implementation of single-use technology for bioproduction
3.2.1.2. Rising demand for biologics
3.2.1.3. Expansion of contract development and manufacturing organizations
3.2.2. Market restraint analysis
3.2.2.1. High initial setup and operational costs for large-scale bioprocessing
3.2.2.2. Complexity and regulatory hurdles
3.3. U.S. Large and Small-scale Bioprocessing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. U.S. Large and Small-scale Bioprocessing Market: Scale Estimates & Trend Analysis
4.1. Scale Segment Dashboard
4.2. U.S. Large and Small-scale Bioprocessing Market Scale Movement Analysis
4.3. U.S. Large and Small-scale Bioprocessing Market Size & Trend Analysis, by Scale, 2021 to 2033 (USD Million)
4.4. Industrial Scale (Over 50,000 Liter)
4.4.1. Industrial scale (Over 50,000 Liter) market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Small Scale (Less Than 50,000 Liter)
4.5.1. Small scale (Less Than 50,000 Liter) market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. U.S. Large and Small-scale Bioprocessing Market: Workflow Estimates & Trend Analysis
5.1. Workflow Segment Dashboard
5.2. U.S. Large and Small-scale Bioprocessing Market Workflow Movement Analysis
5.3. U.S. Large and Small-scale Bioprocessing Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
5.4. Downstream Processing
5.4.1. Downstream processing market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Fermentation
5.5.1. Fermentation market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Upstream Processing
5.6.1. Upstream processing market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. U.S. Large and Small-scale Bioprocessing Market: Product Estimates & Trend Analysis
6.1. Product Segment Dashboard
6.2. U.S. Large and Small-scale Bioprocessing Market Product Movement Analysis
6.3. U.S. Large and Small-scale Bioprocessing Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
6.4. Bioreactors/Fermenters
6.4.1. Bioreactors/fermenters market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Cell Culture Products
6.5.1. Cell culture products market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Filtration Assemblies
6.6.1. Filtration assemblies market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Bioreactors Accessories
6.7.1. Bioreactors accessories market estimates and forecasts 2021 to 2033 (USD Million)
6.8. Bags & Containers
6.8.1. Bags & containers market estimates and forecasts 2021 to 2033 (USD Million)
6.9. Others
6.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. U.S. Large and Small-scale Bioprocessing Market: Application Estimates & Trend Analysis
7.1. Application Segment Dashboard
7.2. U.S. Large and Small-scale Bioprocessing Market Application Movement Analysis
7.3. U.S. Large and Small-scale Bioprocessing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
7.4. Biopharmaceuticals
7.4.1. Biopharmaceuticals market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Speciality Industrial Chemicals
7.5.1. Speciality industrial chemicals market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Environmental Aids
7.6.1. Environmental aids market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. U.S. Large and Small-scale Bioprocessing Market: Use-Type Estimates & Trend Analysis
8.1. Use-Type Segment Dashboard
8.2. U.S. Large and Small-scale Bioprocessing Market Use-Type Movement Analysis
8.3. U.S. Large and Small-scale Bioprocessing Market Size & Trend Analysis, by Use-Type, 2021 to 2033 (USD Million)
8.4. Multi-use
8.4.1. Multi-use market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Single-use
8.5.1. Single-use market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. U.S. Large and Small-scale Bioprocessing Market: Mode Estimates & Trend Analysis
9.1. Mode Segment Dashboard
9.2. U.S. Large and Small-scale Bioprocessing Market Mode Movement Analysis
9.3. U.S. Large and Small-scale Bioprocessing Market Size & Trend Analysis, by Mode, 2021 to 2033 (USD Million)
9.4. In-house
9.4.1. In-house market estimates and forecasts 2021 to 2033 (USD Million)
9.5. Outsourced
9.5.1. Outsourced market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company/Competition Categorization
10.2. Strategy Mapping
10.3. Company Market Position Analysis, 2024
10.4. Company Profiles/Listing
10.4.1. Merck KGaA
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Thermo Fisher Scientific, Inc.
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. Danaher
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Corning Inc.
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Sartorius AG
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Lonza
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Eppendorf AG
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Getinge AB
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Product benchmarking
10.4.8.4. Strategic initiatives
10.4.9. PBS Biotech, Inc.
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Product benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Meissner Filtration Products, Inc.
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Product benchmarking
10.4.10.4. Strategic initiatives
10.4.11. Entegris
10.4.11.1. Company overview
10.4.11.2. Financial performance
10.4.11.3. Product benchmarking
10.4.11.4. Strategic initiatives
10.4.12. Saint-Gobain
10.4.12.1. Company overview
10.4.12.2. Financial performance
10.4.12.3. Product benchmarking
10.4.12.4. Strategic initiatives
10.4.13. Repligen Corporation
10.4.13.1. Company overview
10.4.13.2. Financial performance
10.4.13.3. Product benchmarking
10.4.13.4. Strategic initiatives
10.4.14. Avantor, Inc
10.4.14.1. Company overview
10.4.14.2. Financial performance
10.4.14.3. Product benchmarking
10.4.14.4. Strategic initiatives
10.4.15. Distek, Inc.
10.4.15.1. Company overview
10.4.15.2. Financial performance
10.4.15.3. Product benchmarking
10.4.15.4. Strategic initiatives
10.4.16. F. Hoffmann-La Roche Ltd
10.4.16.1. Company overview
10.4.16.2. Financial performance
10.4.16.3. Product benchmarking
10.4.16.4. Strategic initiatives
10.4.17. Bio-Synthesis, Inc.
10.4.17.1. Company overview
10.4.17.2. Financial performance
10.4.17.3. Product benchmarking
10.4.17.4. Strategic initiatives